PDIA3 orchestrates effector T cell program by serving as a chaperone to facilitate the non-canonical nuclear import of STAT1 and PKM2
Chun-Liang Yang,Fa-Xi Wang,Jia-Hui Luo,Shan-Jie Rong,Wan-Ying Lu,Qi-Jie Chen,Jun Xiao,Ting Wang,Dan-Ni Song,Jing Liu,Qian Mo,Shuo Li,Yu Chen,Ya-Nan Wang,Yan-Jun Liu,Tong Yan,Wei-Kuan Gu,Shu Zhang,Fei Xiong,Qi-Lin Yu,Zi-Yun Zhang,Ping Yang,Shi-Wei Liu,Decio Eizirik,Ling-Li Dong,Fei Sun,Cong-Yi Wang
DOI: https://doi.org/10.1016/j.ymthe.2024.05.038
2024-08-07
Abstract:Dysregulated T cell activation underpins the immunopathology of rheumatoid arthritis (RA), yet the machineries that orchestrate T cell effector program remain incompletely understood. Herein, we leveraged bulk and single-cell RNA sequencing data from RA patients and validated protein disulfide isomerase family A member 3 (PDIA3) as a potential therapeutic target. PDIA3 is remarkably upregulated in pathogenic CD4 T cells derived from RA patients and positively correlates with C-reactive protein level and disease activity score 28. Pharmacological inhibition or genetic ablation of PDIA3 alleviates RA-associated articular pathology and autoimmune responses. Mechanistically, T cell receptor signaling triggers intracellular calcium flux to activate NFAT1, a process that is further potentiated by Wnt5a under RA settings. Activated NFAT1 then directly binds to the Pdia3 promoter to enhance the expression of PDIA3, which complexes with STAT1 or PKM2 to facilitate their nuclear import for transcribing T helper 1 (Th1) and Th17 lineage-related genes, respectively. This non-canonical regulatory mechanism likely occurs under pathological conditions, as PDIA3 could only be highly induced following aberrant external stimuli. Together, our data support that targeting PDIA3 is a vital strategy to mitigate autoimmune diseases, such as RA, in clinical settings.